Insys Therapeutics Company Profile (NASDAQ:INSY)

About Insys Therapeutics

Insys Therapeutics logoInsys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: INSY
  • CUSIP:
Key Metrics:
  • Previous Close: $15.17
  • 50 Day Moving Average: $16.26
  • 200 Day Moving Average: $15.69
  • Trailing P/E Ratio: 22.85
  • Foreward P/E Ratio: 25.28
  • P/E Growth: 1.34
  • Market Cap: $1.09B
  • Outstanding Shares: 71,595,000
  • Beta: 1.98
Additional Links:
Companies Related to Insys Therapeutics:

Analyst Ratings

Consensus Ratings for Insys Therapeutics (NASDAQ:INSY) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $26.80 (76.66% upside)

Analysts' Ratings History for Insys Therapeutics (NASDAQ:INSY)
Show:
DateFirmActionRatingPrice TargetDetails
8/25/2016Piper Jaffray Cos.Reiterated RatingOverweight$28.00View Rating Details
8/4/2016Jefferies GroupReiterated RatingBuy$17.00 -> $22.00View Rating Details
4/30/2016Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details
4/14/2016Janney Montgomery ScottInitiated CoverageBuy$22.00View Rating Details
4/12/2016Royal Bank Of CanadaReiterated RatingOutperform$44.00 -> $32.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$38.00 -> $30.00View Rating Details
(Data available from 8/27/2014 forward)

Earnings

Earnings History for Insys Therapeutics (NASDAQ:INSY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/3/2016Q216$0.07$0.06$66.90 million$67.10 millionViewListenView Earnings Details
4/28/2016Q116$0.07$0.11$61.31 million$62.00 millionViewListenView Earnings Details
2/23/2016Q415$0.29$0.36$91.04 million$91.10 millionViewListenView Earnings Details
11/5/2015Q315$0.23$0.50$82.98 million$91.30 millionViewN/AView Earnings Details
8/6/2015Q215$0.21$0.21$74.06 million$77.60 millionViewN/AView Earnings Details
5/7/2015Q115$0.35$0.63$70.90 million$70.80 millionViewN/AView Earnings Details
3/3/2015Q414$0.44$0.53$63.50 million$66.50 millionViewN/AView Earnings Details
11/11/2014Q314$0.29$0.63$57.10 million$58.30 millionViewN/AView Earnings Details
8/12/2014Q214$0.30$0.58$52.77 million$55.70 millionViewN/AView Earnings Details
5/13/2014Q114$0.28$0.23$45.63 million$41.60 millionViewN/AView Earnings Details
3/4/2014Q413$0.55$0.71$34.73 million$40.20 millionViewN/AView Earnings Details
11/12/2013Q3$0.33$0.58$27.00 million$29.20 millionViewListenView Earnings Details
8/13/2013Q213$0.12$0.35$15.07 million$18.80 millionViewN/AView Earnings Details
6/3/2013Q113$0.01$2.00 million$11.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Insys Therapeutics (NASDAQ:INSY)
Current Year EPS Consensus Estimate: $0.19 EPS
Next Year EPS Consensus Estimate: $0.6 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.05$0.05$0.05
Q2 20161$0.04$0.04$0.04
Q3 20161$0.10$0.10$0.10
Q4 20161$0.13$0.13$0.13
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Insys Therapeutics (NASDAQ:INSY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Insys Therapeutics (NASDAQ:INSY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2016Theodore H StanleyDirectorSell15,000$18.02$270,300.00View SEC Filing  
8/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy5,700$18.57$105,849.00View SEC Filing  
8/11/2016Patrick FourteauDirectorSell15,000$18.46$276,900.00View SEC Filing  
8/9/2016Daniel BrennanVPSell5,781$19.16$110,763.96View SEC Filing  
6/6/2016Theodore H StanleyDirectorSell16,000$16.27$260,320.00View SEC Filing  
5/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy50,000$12.84$642,000.00View SEC Filing  
3/4/2016Patrick FourteauDirectorSell15,000$18.22$273,300.00View SEC Filing  
11/17/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy5,000$29.50$147,500.00View SEC Filing  
11/12/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy10,000$26.58$265,800.00View SEC Filing  
11/12/2015Patrick FourteauDirectorSell30,000$26.48$794,400.00View SEC Filing  
9/14/2015Theodore H. StanleyDirectorSell4,000$37.04$148,160.00View SEC Filing  
6/10/2015Fosse Franc DelGeneral CounselSell10,000$34.48$344,800.00View SEC Filing  
6/5/2015Steven J MeyerDirectorSell5,000$63.00$315,000.00View SEC Filing  
5/27/2015Brian TambiDirectorSell3,100$60.09$186,279.00View SEC Filing  
5/26/2015Brian TambiDirectorSell1,800$60.00$108,000.00View SEC Filing  
5/20/2015Patrick FourteauDirectorSell9,064$60.00$543,840.00View SEC Filing  
5/18/2015Darryl S BakerCFOSell10,000$59.17$591,700.00View SEC Filing  
5/11/2015Steven J MeyerDirectorSell18,000$57.06$1,027,080.00View SEC Filing  
3/17/2015Michael L BabichCEOSell75,000$58.63$4,397,250.00View SEC Filing  
3/11/2015Patrick FourteauDirectorSell10,000$59.94$599,400.00View SEC Filing  
3/10/2015Theodore H StanleyDirectorSell3,300$60.03$198,099.00View SEC Filing  
2/9/2015Darryl S BakerCFOSell30,000$52.23$1,566,900.00View SEC Filing  
11/19/2014Patrick FourteauDirectorSell25,000$39.11$977,750.00View SEC Filing  
11/4/2014Michael L BabichCEOSell80,000$38.66$3,092,800.00View SEC Filing  
8/13/2014Theodore H StanleyDirectorBuy3,000$33.93$101,790.00View SEC Filing  
6/16/2014John N KapoorDirectorBuy5,000$26.13$130,650.00View SEC Filing  
6/13/2014John N KapoorDirectorBuy5,000$25.44$127,200.00View SEC Filing  
6/12/2014John N KapoorDirectorBuy20,000$24.84$496,800.00View SEC Filing  
6/11/2014John N KapoorDirectorBuy20,000$24.54$490,800.00View SEC Filing  
5/19/2014Theodore StanleyDirectorBuy4,000$21.94$87,760.00View SEC Filing  
5/15/2014Patrick FourteauDirectorBuy7,500$22.77$170,775.00View SEC Filing  
3/5/2014Larry DillahaInsiderSell149,932$74.57$11,180,429.24View SEC Filing  
3/5/2014Michael BabichCEOSell288,432$74.58$21,511,258.56View SEC Filing  
1/16/2014Darryl BakerCFOSell10,000$49.61$496,100.00View SEC Filing  
1/15/2014Darryl BakerCFOSell10,000$47.54$475,400.00View SEC Filing  
1/14/2014Darryl BakerCFOSell10,000$45.64$456,400.00View SEC Filing  
12/9/2013John KapoorDirectorSell27,428$47.25$1,295,973.00View SEC Filing  
8/16/2013Michael BabichCEOBuy1,000$24.90$24,900.00View SEC Filing  
8/14/2013Patrick FourteauDirectorBuy5,000$23.77$118,850.00View SEC Filing  
6/4/2013Michael L BabichCEOBuy1,250$10.93$13,662.50View SEC Filing  
5/24/2013Pierre LapalmeDirectorBuy3,000$10.39$31,170.00View SEC Filing  
5/14/2013Patrick FourteauDirectorBuy5,000$10.90$54,500.00View SEC Filing  
5/13/2013Patrick FourteauDirectorBuy4,800$10.90$52,320.00View SEC Filing  
5/7/2013Patrick FourteauDirectorBuy50,000$8.36$418,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Insys Therapeutics (NASDAQ:INSY)
DateHeadline
News IconNew Broker Ratings For Insys Therapeutics, Inc. (INSY) (NASDAQ:INSY)
magseriesusa.net - August 27 at 10:08 AM
reuters.com logoBRIEF-Insys Therapeutics says in study all treatments were generally well tolerated (NASDAQ:INSY)
www.reuters.com - August 26 at 5:31 PM
streetinsider.com logoInsys Therapeutics (INSY) Announces Buprenorphine Sublingual Spray Phase 3 Met Primary Endpoint - StreetInsider.com (NASDAQ:INSY)
www.streetinsider.com - August 26 at 8:39 AM
capitalcube.com logoINSYS Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : INSY-US : August 26, 2016 (NASDAQ:INSY)
www.capitalcube.com - August 26 at 8:39 AM
marketexclusive.com logoBiotech Movers: Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) and Insys Therapeutics Inc (NASDAQ:INSY - Market Exclusive (NASDAQ:INSY)
marketexclusive.com - August 25 at 5:41 PM
finance.yahoo.com logoIllinois attorney general sues Insys over fentanyl drug marketing (NASDAQ:INSY)
finance.yahoo.com - August 25 at 5:41 PM
News IconMost Volatile Healthcare Stocks- SCYNEXIS, Inc. (NASDAQ:SCYX), INSYS Therapeutics (NASDAQ:INSY) - Seneca Globe (NASDAQ:INSY)
www.senecaglobe.com - August 25 at 10:41 AM
bidnessetc.com logoInsys Therapeutics Inc (INSY) Stock Rises on Successful Phase 3 Trial Results - Bidness ETC (NASDAQ:INSY)
www.bidnessetc.com - August 25 at 10:41 AM
globenewswire.com logoInsys Therapeutics Reports Phase 3 Trial of Sublingual Buprenorphine Spray Met Primary Endpoint in Patients with ... - GlobeNewswire (press release) (NASDAQ:INSY)
globenewswire.com - August 25 at 10:41 AM
rttnews.com logoInsys Therapeutics Inc. (INSY) Is Climbing On Phase 3 Study Results (NASDAQ:INSY)
www.rttnews.com - August 24 at 5:33 PM
capitalcube.com logoETF’s with exposure to INSYS Therapeutics, Inc. : August 24, 2016 (NASDAQ:INSY)
www.capitalcube.com - August 24 at 5:33 PM
streetinsider.com logoInsys Therapeutics (INSY) Announces Buprenorphine Sublingual Spray Phase 3 Met Primary Endpoint (NASDAQ:INSY)
www.streetinsider.com - August 24 at 8:47 AM
nasdaq.com logoInsys Therapeutics Reports Phase 3 Trial of Sublingual Buprenorphine Spray Met Primary Endpoint in (NASDAQ:INSY)
www.nasdaq.com - August 24 at 8:47 AM
finance.yahoo.com logoInsys Therapeutics Reports Phase 3 Trial of Sublingual Buprenorphine Spray Met Primary Endpoint in Patients with Moderate-to-Severe Postoperative Pain after Bunionectomy (NASDAQ:INSY)
finance.yahoo.com - August 24 at 8:47 AM
finance.yahoo.com logo6:52 am Insys Therapeutics reports that the Phase 3 trial for the Buprenorphine Sublingual Spray met its primary endpoint (NASDAQ:INSY)
finance.yahoo.com - August 24 at 8:47 AM
nasdaq.com logoInsys Therapeutics Starts Enrollment in Cannabidiol Trial - Nasdaq (NASDAQ:INSY)
www.nasdaq.com - August 21 at 9:58 AM
4-traders.com logoInsys Therapeutics : Ex-Insys employees plead not guilty in U.S. drug-kickback case (NASDAQ:INSY)
www.4-traders.com - August 19 at 5:40 PM
zacks.com logoInsys Therapeutics Starts Enrollment in Cannabidiol Trial (NASDAQ:INSY)
www.zacks.com - August 19 at 5:40 PM
globenewswire.com logoInsys Therapeutics Announces First Patient Enrolled in Phase II Trial ... - GlobeNewswire (press release) (NASDAQ:INSY)
globenewswire.com - August 19 at 8:39 AM
News IconEx-Insys employees plead not guilty in U.S. drug-kickback case - Business Insider (NASDAQ:INSY)
www.businessinsider.com - August 18 at 5:41 PM
globenewswire.com logoInsys Therapeutics Announces First Patient Enrolled in Phase II Trial for the Treatment of Cocaine Dependence Using ... - GlobeNewswire (press release) (NASDAQ:INSY)
globenewswire.com - August 18 at 5:41 PM
reuters.com logoBRIEF-Insys Therapeutics says enrollment of first patient in phase II trial for treatment of cocaine dependence (NASDAQ:INSY)
www.reuters.com - August 18 at 8:43 AM
finance.yahoo.com logoInsys Therapeutics Announces First Patient Enrolled in Phase II Trial for the Treatment of Cocaine Dependence Using Pharmaceutical Cannabidiol (NASDAQ:INSY)
finance.yahoo.com - August 18 at 8:43 AM
reuters.com logoBRIEF-Ennis entered into sixth amendment to second amended and restated credit agreement (NASDAQ:INSY)
www.reuters.com - August 17 at 5:53 PM
reuters.com logoBRIEF-Baker Brosadvisors LP'S Felix Baker reports a passive stake of 14.99 pct in Biocryst Pharmaceuticals (NASDAQ:INSY)
uk.reuters.com - August 17 at 5:53 PM
streetinsider.com logoForm 4 Insys Therapeutics, Inc. For: Aug 16 Filed by: STANLEY THEODORE H (NASDAQ:INSY)
www.streetinsider.com - August 17 at 8:44 AM
finance.yahoo.com logoINSYS THERAPEUTICS, INC. Financials (NASDAQ:INSY)
finance.yahoo.com - August 16 at 5:48 PM
biz.yahoo.com logoINSYS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:INSY)
biz.yahoo.com - August 11 at 5:54 PM
247wallst.com logoWhy Jefferies Sees 3 Big Biotechs Having Key Upside Catalysts Coming (NASDAQ:INSY)
247wallst.com - August 11 at 8:46 AM
investornewswire.com logoInsys Therapeutics, Inc. (NASDAQ:INSY) Brokerage Rating Update - Investor Newswire (NASDAQ:INSY)
www.investornewswire.com - August 10 at 5:58 PM
4-traders.com logoInsys Therapeutics : Identifying Newest Cannabis Strains for Cancer Treatment and Other Ailments Gain Headway Behind Pharmacological Evaluations (NASDAQ:INSY)
www.4-traders.com - August 10 at 8:34 AM
finance.yahoo.com logoIdentifying Newest Cannabis Strains for Cancer Treatment and Other Ailments Gain Headway Behind Pharmacological Evaluations (NASDAQ:INSY)
finance.yahoo.com - August 10 at 8:34 AM
capitalcube.com logoETF’s with exposure to INSYS Therapeutics, Inc. : August 8, 2016 (NASDAQ:INSY)
www.capitalcube.com - August 8 at 5:51 PM
capitalcube.com logoINSYS Therapeutics, Inc. :INSY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:INSY)
www.capitalcube.com - August 5 at 5:49 PM
biz.yahoo.com logoINSYS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:INSY)
biz.yahoo.com - August 5 at 5:49 PM
News IconTime To Put On The Watch List? – INSYS Therapeutics (NASDAQ ... - The Voice Registrar (NASDAQ:INSY)
voiceregistrar.com - August 5 at 8:42 AM
streetupdates.com logoTraders Actions to Focus: Waters Corporation (NYSE:WAT) , Insys Therapeutics, Inc. (NASDAQ:INSY) - Street Updates (NASDAQ:INSY)
www.streetupdates.com - August 5 at 8:42 AM
equities.com logoInsys Therapeutics Inc. (INSY) Jumps 17.43% on August 03 - Equities.com (NASDAQ:INSY)
www.equities.com - August 5 at 8:42 AM
News IconFour Marijuana Companies You Should Be Looking At In The Coming Months (NASDAQ:INSY)
marijuanastocks.com - August 4 at 5:58 PM
capitalcube.com logoINSYS Therapeutics, Inc.: Gathering momentum, can it sustain its performance? (NASDAQ:INSY)
www.capitalcube.com - August 4 at 5:58 PM
tradecalls.org logoAnalyst Rating Update on Insys Therapeutics (INSY) – Trade Calls - Trade Calls (NASDAQ:INSY)
www.tradecalls.org - August 4 at 8:43 AM
finance.yahoo.com logoEdited Transcript of INSY earnings conference call or presentation 3-Aug-16 2:00pm GMT (NASDAQ:INSY)
finance.yahoo.com - August 4 at 8:43 AM
reuters.com logoBRIEF-Insys Therapeutics Q2 earnings per share $0.06 - Reuters (NASDAQ:INSY)
www.reuters.com - August 3 at 5:59 PM
biz.yahoo.com logoINSYS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:INSY)
biz.yahoo.com - August 3 at 5:59 PM
biz.yahoo.com logoINSYS Therapeutics Inc Earnings Call (Q2 2016) (NASDAQ:INSY)
biz.yahoo.com - August 3 at 8:54 AM
nasdaq.com logoInsys Therapeutics Reports Second Quarter 2016 Results (NASDAQ:INSY)
www.nasdaq.com - August 3 at 8:54 AM
sg.finance.yahoo.com logoInsys Therapeutics tops 2Q profit forecasts (NASDAQ:INSY)
sg.finance.yahoo.com - August 3 at 8:54 AM
biz.yahoo.com logoQ2 2016 INSYS Therapeutics Inc Earnings Release - Before Market Open (NASDAQ:INSY)
biz.yahoo.com - August 3 at 8:54 AM
sbwire.com logoRising Number of People Diagnosed with Malignant Glioma Supports the Growth of the Global Adult Malignant Glioma Therapeutics Market (NASDAQ:INSY)
www.sbwire.com - July 28 at 5:49 PM
openpr.com logoAdult Malignant Glioma Therapeutics Market Insights into pharmaceutical industry (NASDAQ:INSY)
www.openpr.com - July 28 at 8:42 AM

Social

Insys Therapeutics (NASDAQ:INSY) Chart for Saturday, August, 27, 2016


Last Updated on 8/27/2016 by MarketBeat.com Staff